Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Research Use Only

Phage-based detection assays benefit from the selectivity of a phage for a specific bacterial target.

Loading...
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...

ACTIPHAGE MTB COMPONENTS FOR RUO

PBD Biotech is to make components of its Actiphage diagnostic available for Research Use Only (RUO). Actiphage is able to detect mycobacteria belonging to the Mycobacterium tuberculosis complex (MTBC) including M. tuberculosis (Mtb), in a 2-5 ml human blood sample.

Actiphage offers a rapid assay (24/48 hours to result) utilising patented bacteriophage technology to infect and lyse live mycobacteria and release its DNA, which can then be used as a target to detect Mtb by qPCR.

Actiphage box

COMPONENTS

Instructions for use (IFU)

A comprehensive set of instructions describing the set up and interpretation of results using the Actiphage RUO components for detection of Mtb in human blood is provided.

White blood cells isolation reagents

Mtb are sequestered by peripheral blood mononuclear cells (PBMCs). PBD Biotech has validated a robust, reproducible method to isolate intact PBMCs from a fresh sample of human whole blood, for exposure to and infection by our phage technology - Actiphage.

Actiphage incubation reagents

Optimal amount of freeze-dried phage particles are provided for successful Mtb infection, lysis and recovery of released DNA.

DNA clean up reagents and spin columns

All the reagents required to remove any residual inhibitory substances from the phage infection assay and to purify and concentrate the DNA released from the Mtb ready for efficient downstream qPCR analysis are included.

Positive control

Freeze-dried attenuated M.bovis BCG strain is supplied as a positive control. A positive control determines whether the pre-PCR sample-processing and PCR reaction conditions are optimal. It allows assessment of any enzymatic inhibitors and/or technical issues that may interfere with the efficiency of the pre-PCR sample-processing steps and PCR, giving confidence that the test is performing to the technical specifications detailed in the IFU.

Internal positive control

Exogenous DNA template is supplied as an internal positive control (IPC). An IPC is added to each reaction to monitor the PCR assay performance and detect amplification inhibitors and false-negative results.

Negative control

Nuclease free water is supplied as a no-template control (NTC). An NTC omits any DNA template from the reaction and serves as a general control for extraneous nucleic acid contamination. 
Internal positive control

Exogenous DNA template is supplied as an internal positive control (IPC). An IPC is added to each reaction to monitor the PCR assay performance and detect amplification inhibitors and false-negative results.

PCR assay reagents

Lyophilised PCR reaction beads containing polymerase enzyme, dNTPs, oligonucleotide primers and probes and PCR additives.

The primers and probes allow specific detection of DNA lysed from Mtb isolated from a human whole blood sample.

Actiphage in your lab

If you would like to find out more about how your lab could be meeting the requirement of the huge market for improved tuberculosis diagnostics then get in contact.

Researchers at Leicester Respiratory NIHR Biomedical Centre (2022) used Actiphage to screen high risk patients.

It was the first study to successfully isolate Mtb in the blood and to use this to distinguish between latent TBI and incipient TBI.

Showed bacteraemia (bacteria in the blood) can be used to provide early-stage diagnosis.

Demonstrated that Actiphage had potential for rapid blood test for screening vulnerable populations.

The research was presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases

Related content

Loading...
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

November 21, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

November 21, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in...
Actiphage journey 2022

WHO Target Product Profile (TPP) for Tuberculosis

November 14, 2022
For some of the world's most infectious diseases, such as tuberculosis (TB), The WHO has developed target product profiles (TPPs) to assist developers of new diagnostics.
Actiphage journey 2022

WHO Target Product Profile (TPP) for Tuberculosis

November 14, 2022
For some of the world's most infectious diseases, such as tuberculosis (TB), The WHO has developed target product profiles (TPPs)...
Five categories of TB

Who is most at risk of developing TB?

November 14, 2022
Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected person coughs or sneezes. Many people carry the disease without realising, creating a reservoir of disease in a population.
Five categories of TB

Who is most at risk of developing TB?

November 14, 2022
Tuberculosis (TB) is a bacterial infection that is spread by inhaling tiny droplets in the air released when an infected...
TB Progression in humans

Rapid screening of high risk populations for latent TB

November 14, 2022
Estimates suggest that a third of the people in the world have latent TB - this is more than 13 million people in the US. Not all are at risk of the disease, so diagnostics are needed for targeting treatment.
TB Progression in humans

Rapid screening of high risk populations for latent TB

November 14, 2022
Estimates suggest that a third of the people in the world have latent TB - this is more than 13...
1 2 … 6 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More